New Amsterdam Pharma CO N.V. NAMS
We take great care to ensure that the data presented and summarized in this overview for NewAmsterdam Pharma Co N.V. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NAMS
Top Purchases
Top Sells
About NAMS
Insider Transactions at NAMS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 07
2026
|
Kamp Hilde Johanna Van Der |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+24.71%
|
-
|
|
Jan 07
2026
|
Louis G Lange |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+24.71%
|
-
|
|
Jan 07
2026
|
Mark C. Mc Kenna |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+24.71%
|
-
|
|
Jan 07
2026
|
John W Smither |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+24.71%
|
-
|
|
Jan 07
2026
|
William Lewis |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+24.71%
|
-
|
|
Jan 07
2026
|
Michael H. Davidson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
81,000
+14.98%
|
-
|
|
Jan 07
2026
|
Michael H. Davidson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,582
-2.97%
|
-
|
|
Jan 07
2026
|
Adele M. Gulfo |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+19.25%
|
-
|
|
Jan 07
2026
|
Johannes Jacob Pieter Kastelein Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,500
+20.49%
|
-
|
|
Jan 07
2026
|
Mayur Ian Somaiya Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,500
+30.4%
|
-
|
|
Jan 07
2026
|
Louise Frederika Kooij Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+33.01%
|
-
|
|
Jan 05
2026
|
Johannes Jacob Pieter Kastelein Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,000
-7.55%
|
$198,000
$33.25 P/Share
|
|
Jan 05
2026
|
Mayur Ian Somaiya Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,118
-13.47%
|
$168,894
$33.25 P/Share
|
|
Jan 05
2026
|
Louise Frederika Kooij Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,647
-17.65%
|
$87,351
$33.25 P/Share
|
|
Dec 26
2025
|
Louise Frederika Kooij Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
43,872
-74.52%
|
$1,535,520
$35.3 P/Share
|
|
Dec 26
2025
|
Louise Frederika Kooij Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,872
+24.87%
|
$438,720
$10.45 P/Share
|
|
Dec 24
2025
|
Louise Frederika Kooij Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
26,011
-63.42%
|
$910,385
$35.68 P/Share
|
|
Dec 24
2025
|
Louise Frederika Kooij Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,011
+38.81%
|
$260,110
$10.0 P/Share
|
|
Dec 23
2025
|
Louise Frederika Kooij Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
75,117
-83.36%
|
$2,704,212
$36.21 P/Share
|
|
Dec 23
2025
|
Louise Frederika Kooij Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,117
+45.46%
|
$751,170
$10.0 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.89M
Shares
From
18
Insiders
| Grant, award, or other acquisition | 281K shares |
|---|---|
| Open market or private purchase | 19.9K shares |
| Exercise of conversion of derivative security | 1.59M shares |
Sell / Disposition
1.49M
Shares
From
5
Insiders
| Open market or private sale | 1.49M shares |
|---|